Jaguar Health 8/13/2024 Earnings Report $0.93 +0.05 (+6.00%) (As of 12/20/2024 05:40 PM ET) Earnings History Jaguar Health EPS ResultsActual EPS-$4.04Consensus EPS -$1.20Beat/MissMissed by -$2.84One Year Ago EPSN/AJaguar Health Revenue ResultsActual Revenue$2.72 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AJaguar Health Announcement DetailsQuarterDate8/13/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptJAGX Earnings History Your chance to get on the next “60-Second Trade” (Ad)Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!Just head over here! Jaguar Health Earnings HeadlinesJaguar Health announces import of coca leaf by Magdalena Biosciences JVDecember 20 at 8:30 PM | markets.businessinsider.comU.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health’s Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) BeginsDecember 6, 2024 | markets.businessinsider.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.December 22, 2024 | Crypto Swap Profits (Ad)Jaguar Health seeking partner to develop, commercialize NP300November 23, 2024 | markets.businessinsider.comJaguar Health, Inc.: Jaguar Health Family Company Napo Therapeutics Named "Best Pharmaceuticals Innovator of the Year - Europe"November 20, 2024 | finanznachrichten.deJaguar Health, Inc. (NASDAQ:JAGX) Q3 2024 Earnings Call TranscriptNovember 16, 2024 | msn.comSee More Jaguar Health Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Jaguar Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jaguar Health and other key companies, straight to your email. Email Address About Jaguar HealthJaguar Health (NASDAQ:JAGX), a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.View Jaguar Health ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
